

Yasuko Iwakiri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1452669/publications.pdf>

Version: 2024-02-01

68
papers

4,340
citations

109137

35
h-index

118652

62
g-index

97
all docs

97
docs citations

97
times ranked

5353
citing authors

#	ARTICLE	IF	CITATIONS
1	Nitric oxide facilitates the targeting Kupffer cells of a nano-antioxidant for the treatment of NASH. <i>Journal of Controlled Release</i> , 2022, 341, 457-474.	4.8	8
2	Covid-19 and Liver Injury: Role of Inflammatory Endotheliopathy, Platelet Dysfunction, and Thrombosis. <i>Hepatology Communications</i> , 2022, 6, 255-269.	2.0	41
3	Inhibition of high-fat diet-induced obesity via reduction of ER-resident protein Nogo occurs through multiple mechanisms. <i>Journal of Biological Chemistry</i> , 2022, 298, 101561.	1.6	7
4	Hepatic lymphatic vascular system in health and disease. <i>Journal of Hepatology</i> , 2022, 77, 206-218.	1.8	19
5	Enhanced Meningeal Lymphatic Drainage Ameliorates Neuroinflammation and Hepatic Encephalopathy in Cirrhotic Rats. <i>Gastroenterology</i> , 2021, 160, 1315-1329.e13.	0.6	45
6	Lymphatic Dysfunction as a Novel Therapeutic Target in Nonalcoholic Steatohepatitis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 663-664.	2.3	0
7	Single-Cell Transcriptomics Reveals Zone-Specific Alterations of Liver Sinusoidal Endothelial Cells in Cirrhosis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 1139-1161.	2.3	91
8	Pathological characteristics of liver sinusoidal thrombosis in COVID-19 patients: A series of 43 cases. <i>Hepatology Research</i> , 2021, 51, 1000-1006.	1.8	24
9	Alcohol-induced Hsp90 acetylation is a novel driver of liver sinusoidal endothelial dysfunction and alcohol-related liver disease. <i>Journal of Hepatology</i> , 2021, 75, 377-386.	1.8	31
10	Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy. <i>JHEP Reports</i> , 2021, 3, 100316.	2.6	61
11	Obituary for Roberto J. Groszmann "The Father of Portal Hypertension. <i>Hepatology</i> , 2021, 74, 1724-1726.	3.6	0
12	Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy. <i>Journal of Hepatology</i> , 2021, 75, 647-658.	1.8	67
13	Reduced Nogo expression inhibits diet-induced metabolic disorders by regulating ChREBP and insulin activity. <i>Journal of Hepatology</i> , 2020, 73, 1482-1495.	1.8	24
14	Endothelial Leukocyte Cell-Derived Chemotaxin 2/Tyrosine Kinase With Immunoglobulin-Like and Epidermal Growth Factor-Like Domains 1 Signaling in Liver Fibrosis. <i>Hepatology</i> , 2020, 72, 347-349.	3.6	6
15	The lymphatic system in alcohol-associated liver disease. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 633-638.	4.5	3
16	Digoxin improves steatohepatitis with differential involvement of liver cell subsets in mice through inhibition of PKM2 transactivation. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 317, G387-G397.	1.6	25
17	Poly(amine-co-ester) nanoparticles for effective Nogo-B knockdown in the liver. <i>Journal of Controlled Release</i> , 2019, 304, 259-267.	4.8	23
18	O-GlcNAc transferase suppresses necroptosis and liver fibrosis. <i>JCI Insight</i> , 2019, 4, .	2.3	60

#	ARTICLE	IF	CITATIONS
19	Development of Kupffer cell targeting type-I interferon for the treatment of hepatitis via inducing anti-inflammatory and immunomodulatory actions. <i>Drug Delivery</i> , 2018, 25, 1055-1065.	2.5	10
20	Is miR-21 a potent target for liver fibrosis?. <i>Hepatology</i> , 2018, 67, 2082-2084.	3.6	9
21	The portal hypertension syndrome: etiology, classification, relevance, and animal models. <i>Hepatology International</i> , 2018, 12, 1-10.	1.9	81
22	Biology of portal hypertension. <i>Hepatology International</i> , 2018, 12, 11-23.	1.9	67
23	Integrated analysis of microRNA and mRNA expression profiles in splenomegaly induced by non-cirrhotic portal hypertension in rats. <i>Scientific Reports</i> , 2018, 8, 17983.	1.6	3
24	Lymphatics in the liver. <i>Current Opinion in Immunology</i> , 2018, 53, 137-142.	2.4	41
25	An endoplasmic reticulum protein, Nogo66, facilitates alcoholic liver disease through regulation of kupffer cell polarization. <i>Hepatology</i> , 2017, 65, 1720-1734.	3.6	68
26	Reply. <i>Hepatology</i> , 2017, 65, 2134-2134.	3.6	0
27	Alcohol and calcium make a potent cocktail. <i>Journal of Physiology</i> , 2017, 595, 3109-3110.	1.3	1
28	Reply. <i>Hepatology</i> , 2017, 66, 1702-1703.	3.6	0
29	Novel application and serial evaluation of tissue-engineered portal vein grafts in a murine model. <i>Regenerative Medicine</i> , 2017, 12, 929-938.	0.8	4
30	Comparative efficacy and safety of antibody induction therapy for the treatment of kidney: a network meta-analysis. <i>Oncotarget</i> , 2017, 8, 66426-66437.	0.8	1
31	The lymphatic system: A new frontier in hepatology. <i>Hepatology</i> , 2016, 64, 706-707.	3.6	21
32	The Hepatic Lymphatic Vascular System: Structure, Function, Markers, and Lymphangiogenesis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2016, 2, 733-749.	2.3	97
33	Cellular distribution of injected PLGA-nanoparticles in the liver. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016, 12, 1365-1374.	1.7	103
34	Pigment Epithelium-Derived Factor (PEDF) Inhibits Wnt/ β -catenin Signaling in the Liver. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2015, 1, 535-549.e14.	2.3	32
35	Nitric oxide in liver fibrosis: The role of inducible nitric oxide synthase. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 319.	4.5	84
36	Nitric oxide in liver diseases. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 524-536.	4.0	193

#	ARTICLE	IF	CITATIONS
37	Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension. <i>Journal of Hepatology</i> , 2015, 62, 325-331.	1.8	65
38	Can hypersplenism secondary to portal hypertension be treated by non-selective beta blockers?. <i>Hepatology International</i> , 2015, 9, 337-338.	1.9	2
39	Nonalcoholic fatty liver disease induced by noncanonical Wnt and its rescue by Wnt3a. <i>FASEB Journal</i> , 2015, 29, 3436-3445.	0.2	50
40	Hepatic congestion leads to fibrosis: Findings in a newly developed murine model. <i>Hepatology</i> , 2015, 61, 428-430.	3.6	6
41	Development of Small Diameter Nanofiber Tissue Engineered Arterial Grafts. <i>PLoS ONE</i> , 2015, 10, e0120328.	1.1	56
42	Pathophysiology of Portal Hypertension. <i>Clinics in Liver Disease</i> , 2014, 18, 281-291.	1.0	208
43	Reticulon 4 Is Necessary for Endoplasmic Reticulum Tubulation, STIM1-Orai1 Coupling, and Store-operated Calcium Entry. <i>Journal of Biological Chemistry</i> , 2014, 289, 9380-9395.	1.6	62
44	Vascular pathobiology in chronic liver disease and cirrhosis – Current status and future directions. <i>Journal of Hepatology</i> , 2014, 61, 912-924.	1.8	246
45	Pathophysiology of Portal Hypertension. , 2014, , 3-14.		4
46	Absence of Nogo-B (Reticulon 4B) Facilitates Hepatic Stellate Cell Apoptosis and Diminishes Hepatic Fibrosis in Mice. <i>American Journal of Pathology</i> , 2013, 182, 786-795.	1.9	24
47	Reticulon 4B (Nogo-B) facilitates hepatocyte proliferation and liver regeneration in mice. <i>Hepatology</i> , 2013, 57, 1992-2003.	3.6	31
48	The lymphatic vascular system in liver diseases: its role in ascites formation. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 99.	4.5	70
49	A role of miR-33 for cell cycle progression and cell proliferation. <i>Cell Cycle</i> , 2012, 11, 1057-1057.	1.3	14
50	Proteomic Identification of S-Nitrosylated Golgi Proteins: New Insights into Endothelial Cell Regulation by eNOS-Derived NO. <i>PLoS ONE</i> , 2012, 7, e31564.	1.1	25
51	Endothelial dysfunction in the regulation of cirrhosis and portal hypertension. <i>Liver International</i> , 2012, 32, 199-213.	1.9	156
52	Intestinal and plasma VEGF levels in cirrhosis: the role of portal pressure. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 1125-1133.	1.6	40
53	Pigment Epithelium-Derived Factor Regulates Early Pancreatic Fibrotic Responses and Suppresses the Profibrotic Cytokine Thrombospondin-1. <i>American Journal of Pathology</i> , 2011, 179, 2990-2999.	1.9	23
54	S-nitrosylation of proteins: A new insight into endothelial cell function regulated by eNOS-derived NO. <i>Nitric Oxide - Biology and Chemistry</i> , 2011, 25, 95-101.	1.2	31

#	ARTICLE	IF	CITATIONS
55	Reticulon 4B (Nogo-B) is a novel regulator of hepatic fibrosis. <i>Hepatology</i> , 2011, 53, 1306-1315.	3.6	52
56	The Systemic and Splanchnic Circulations. , 2011, , 305-321.		2
57	The Molecules. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, S288-S294.	1.1	69
58	Vascular endothelial dysfunction in cirrhosis. <i>Journal of Hepatology</i> , 2007, 46, 927-934.	1.8	273
59	Increased neuronal nitric oxide synthase interaction with soluble guanylate cyclase contributes to the splanchnic arterial vasodilation in portal hypertensive rats. <i>Hepatology Research</i> , 2007, 37, 58-67.	1.8	18
60	Increased phosphodiesterase-5 expression is involved in the decreased vasodilator response to nitric oxide in cirrhotic rat livers. <i>Journal of Hepatology</i> , 2006, 44, 886-893.	1.8	47
61	The hyperdynamic circulation of chronic liver diseases: From the patient to the molecule. <i>Hepatology</i> , 2006, 43, S121-S131.	3.6	523
62	Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 290, G980-G987.	1.6	176
63	Nitric oxide synthase generates nitric oxide locally to regulate compartmentalized protein S-nitrosylation and protein trafficking. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 19777-19782.	3.3	232
64	Targeting of Endothelial Nitric-oxide Synthase to the Cytoplasmic Face of the Golgi Complex or Plasma Membrane Regulates Akt- Versus Calcium-dependent Mechanisms for Nitric Oxide Release. <i>Journal of Biological Chemistry</i> , 2004, 279, 30349-30357.	1.6	119
65	Mesenteric vasoconstriction triggers nitric oxide overproduction in the superior mesenteric artery of portal hypertensive rats. <i>Gastroenterology</i> , 2003, 125, 1452-1461.	0.6	79
66	A liver-specific nitric oxide donor improves the intra-hepatic vascular response to both portal blood flow increase and methoxamine in cirrhotic rats. <i>Journal of Hepatology</i> , 2003, 39, 940-946.	1.8	75
67	Mice with targeted deletion of eNOS develop hyperdynamic circulation associated with portal hypertension. <i>American Journal of Physiology - Renal Physiology</i> , 2002, 283, G1074-G1081.	1.6	77
68	Phosphorylation of eNOS initiates excessive NO production in early phases of portal hypertension. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2002, 282, H2084-H2090.	1.5	75